Jiawei Zhao

Since joining Kirkland, Jiawei has been involved in the following matters: 

Initial Public Offering

• Shanghai Longcheer Technology Co., Ltd. (SH: 603341; HKSE: 9611) on its HK$1.62 billion global offering and listing on the Main Board of the Hong Kong Stock Exchange
• The joint sponsors, UBS Securities Hong Kong Limited, China International Capital Corporation Hong Kong, Ping An of China Capital (Hong Kong) Company Limited and GF Capital (Hong Kong) Limited, and underwriters on the HK$4.8 billion global offering and listing of OmniVision Integrated Circuits Group, Inc. (SH: 603501; HKSE: 0501), a global fabless semiconductor design company, on the Main Board of the Hong Kong Stock Exchange
• Suzhou Ribo Life Science Co., Ltd. (HKSE: 6938) on its global offering and listing on the Hong Kong Stock Exchange. The IPO raised approximately HK$1.83 billion after the full exercise of Offer Size Adjustment Option. Ribo Life is a leading biopharmaceutical company specializing in siRNA therapeutics
• The sole sponsor, Huatai Financial Holdings (Hong Kong) Limited, and the underwriters on the global offering and listing of Shanghai Iluvatar CoreX Semiconductor Co., Ltd. (HKSE: 9903) on the Hong Kong Stock Exchange. Iluvatar CoreX is a leading player in China’s general-purpose GPU industry
• CF PharmTech, Inc. (HKSE: 2652) on its global offering and listing on the Main Board of the Hong Kong Stock Exchange. The Hong Kong public offering tranche was oversubscribed by approximately 6,700 times, ranking among the top three most oversubscribed IPOs on the HKEx in 2025
• Contemporary Amperex Technology Co., Limited (CATL) on its global offering and listing on the Hong Kong Stock Exchange. The IPO raised approximately HK$41 billion (US$5.3 billion) after the exercise of the over-allotment option. CATL is a global leader in new energy innovative technologies, primarily engaged in the research, development, production, and sales of EV and ESS batteries. This transaction was named “Best Equity Deal (APAC and Hong Kong)” and "Highly commended Best IPO (Hong Kong)" by FinanceAsia Achievement Awards 2025
• The joint sponsors and underwriters on the global offering and listing of Dida Inc. (HKSE: 2559) on The Stock Exchange of Hong Kong Limited on June 28, 2024. China International Capital Corporation Hong Kong Securities Limited, Haitong International Capital Limited and Nomura International (Hong Kong) Limited acted as the joint sponsors for this transaction
• iMotion Automotive Technology (Suzhou) Co., Ltd. (“iMotion”) (HKSE: 1274) on the initial public offering of H shares and listed on the Main Board of the Hong Kong Stock Exchange. As the first company specializing in autonomous driving listed on the Hong Kong Stock Exchange, iMotion is an autonomous driving solution provider with a focus on AD domain controllers
• ZX Inc. (HKSE: 9890), a leading online game products publisher in China, on its global offering and listing on the Hong Kong Exchanges and Clearing Limited on September 28, 2023

Other Securities Offerings

• Tanwan Inc. (HKSE: 9890), a leading online game products publisher in China, in connection with its issuance of HK$468 million of zero coupon convertible bonds due 2027
• iMotion Automotive Technology (Suzhou) Co., Ltd. (“iMotion”) (HKSE: 1274) in connection with its H-share placing completed on July 21, 2025. The net proceeds from the H-Share Placing (after deducting all fees, costs and expenses incurred by iMotion) amounted to approximately HK$230 million
• iMotion Automotive Technology (Suzhou) Co., Ltd. (“iMotion”) (HKSE: 1274) in connection with its H-share placing. The net proceeds from the H-Share Placing (after deducting all fees, costs and expenses incurred by iMotion) amounted to approximately HK$228.37 million
• iMotion Automotive Technology (Suzhou) Co., Ltd. (“iMotion”) (HKSE: 1274) in connection with its H-share placing. The net proceeds from the H-Share Placing (after deducting all fees, costs and expenses incurred by iMotion) amounted to approximately HK$73.28 million

Post-Listing Legal Compliance

• Providing post-listing legal compliance service for Zhaoke Ophthalmology Limited (HKSE: 6622), a Chapter 18A biotech company
• Providing post-listing legal compliance service for Yihai International Holdings Ltd. (HKSE: 1579)

Prior to joining Kirkland, Jiawei was involved in the following matters:

Initial Public Offering

• Sirnaomics Ltd. (HKSE: 2257), as the counsel to the issuer in its initial public offering and listing on the Hong Kong Stock Exchange
• Angelalign Technology Inc. (HKSE: 6699), as the counsel to the joint sponsors and joint global coordinators Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited on its US$375 million initial public offering and listing on the Hong Kong Stock Exchange
• HBM Holdings Limited (HKSE: 2142), as counsel to the joint sponsors Morgan Stanley Asia Limited, Merrill Lynch (Asia Pacific) Limited, CLSA Capital Markets Limited and joint global coordinators China International Capital Corporation Hong Kong Securities Limited and Credit Suisse (Hong Kong) Limited on its US$220 million initial public offering and listing on the Hong Kong Stock Exchange
• Hygeia Healthcare Holdings Co., Ltd. (HKSE: 6078), as counsel to Morgan Stanley Asia Limited, Haitong International Securities Company Limited and Huatai Financial Holdings (Hong Kong) Limited as the lead underwriters, on its US$282 million initial public offering and listing on the Hong Kong Stock Exchange
• XD Inc. (HKSE: 2400), as issuer's counsel to its US$90.21 million initial public offering and listing on the Hong Kong Stock Exchange
• Sinic Holdings (Group) Company Limited (HKSE: 2103), as counsel to ABCI Capital Limited and Huatai Financial Holdings (Hong Kong) Limited as the joint sponsors, on its US$268 million initial public offering and listing on the Hong Kong Stock Exchange

Post-Listing Legal Compliance

• Providing post-listing legal compliance service for Shanghai Electric Group Company Limited (HKSE: 2727), an "A+H" company
• Providing post-listing legal compliance service for XD Inc. (HKSE: 2400), a red chip company adopting VIE structure